Optimum technique to reduce risk of stent thrombosis – Authors' reply

Gregg W. Stone; Runlin Gao; Takeshi Kimura; Charles Simonton; Patrick W. Serruys

doi:10.1016/S0140-6736(16)30772-3

Optimum technique to reduce risk of stent thrombosis – Authors' reply

Gregg W. Stone, Runlin Gao, Takeshi Kimura, Charles Simonton, Patrick W. Serruys

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English
Pages (from-to)	127-128
Number of pages	2
Journal	The Lancet
Volume	388
Issue number	10040
DOIs	https://doi.org/10.1016/S0140-6736(16)30772-3
State	Published - 9 Jul 2016
Externally published	Yes

Access to Document

10.1016/S0140-6736(16)30772-3

Cite this

@article{e0ff9ba1d9a74c5cba06b90e52e9c8bc,

title = "Optimum technique to reduce risk of stent thrombosis – Authors' reply",

author = "Stone, {Gregg W.} and Runlin Gao and Takeshi Kimura and Charles Simonton and Serruys, {Patrick W.}",

note = "Funding Information: GWS has served as a consultant to Osprey, Reva, Boston Scientific, AstraZeneca, Eli Lilly–Daiichi Sankyo partnership, InspireMD, TherOx, Atrium, Volcano, InfraReDx, Miracor, Velomedix, CSI, and Matrizyme, and has stock or stock options with Biostar family of funds, MedFocus family of funds, Caliber, Guided Delivery Systems, Micardia, VNT, Cagent, and Qool Therapeutics. RG has a research grant from Abbott Vascular. TK is an advisory board member for Abbott Vascular. CS is a full-time employee of Abbott Vascular. PWS declares no competing interests.",

year = "2016",

month = jul,

day = "9",

doi = "10.1016/S0140-6736(16)30772-3",

language = "English",

volume = "388",

pages = "127--128",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Ltd.",

number = "10040",

}

TY - JOUR

T1 - Optimum technique to reduce risk of stent thrombosis – Authors' reply

AU - Stone, Gregg W.

AU - Gao, Runlin

AU - Kimura, Takeshi

AU - Simonton, Charles

AU - Serruys, Patrick W.

N1 - Funding Information: GWS has served as a consultant to Osprey, Reva, Boston Scientific, AstraZeneca, Eli Lilly–Daiichi Sankyo partnership, InspireMD, TherOx, Atrium, Volcano, InfraReDx, Miracor, Velomedix, CSI, and Matrizyme, and has stock or stock options with Biostar family of funds, MedFocus family of funds, Caliber, Guided Delivery Systems, Micardia, VNT, Cagent, and Qool Therapeutics. RG has a research grant from Abbott Vascular. TK is an advisory board member for Abbott Vascular. CS is a full-time employee of Abbott Vascular. PWS declares no competing interests.

PY - 2016/7/9

Y1 - 2016/7/9

UR - http://www.scopus.com/inward/record.url?scp=84979633215&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(16)30772-3

DO - 10.1016/S0140-6736(16)30772-3

M3 - Letter

C2 - 27411875

AN - SCOPUS:84979633215

SN - 0140-6736

VL - 388

SP - 127

EP - 128

JO - The Lancet

JF - The Lancet

IS - 10040

ER -